Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022

She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all

MGC inks agreement to revolutionize allergy care

Merck receives positive EU CHMP opinions for pembrolizumab regimens for gynecologic cancers

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma

Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO

She brings an overall Techno Commercial experience of 22+ Years in various Organizations

Brinton Pharmaceuticals launches UV DOUX lip lightening balm in India

Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day

Astec Lifesciences appoints Prof. G. D. Yadav as Independent Director

Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India

Aragen receives SBTi approval for its greenhouse gas emission reduction targets

Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval

10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab

Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC

KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival

Laurus Labs inaugurates Rs. 250 crore R&D facility in Telangana

Total investment incurred for setting up the new R&D Rs 250 crore